|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ITGB1BP1 |
Gene summary for ITGB1BP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ITGB1BP1 | Gene ID | 9270 |
| Gene name | integrin subunit beta 1 binding protein 1 | |
| Gene Alias | ICAP-1A | |
| Cytomap | 2p25.1 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | O14713 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9270 | ITGB1BP1 | LZE4T | Human | Esophagus | ESCC | 3.19e-22 | 7.32e-01 | 0.0811 |
| 9270 | ITGB1BP1 | LZE5T | Human | Esophagus | ESCC | 9.94e-04 | 2.39e-01 | 0.0514 |
| 9270 | ITGB1BP1 | LZE7T | Human | Esophagus | ESCC | 1.76e-07 | 6.14e-01 | 0.0667 |
| 9270 | ITGB1BP1 | LZE20T | Human | Esophagus | ESCC | 1.83e-03 | 2.09e-01 | 0.0662 |
| 9270 | ITGB1BP1 | LZE22T | Human | Esophagus | ESCC | 4.25e-04 | 9.11e-01 | 0.068 |
| 9270 | ITGB1BP1 | LZE24T | Human | Esophagus | ESCC | 3.49e-19 | 7.05e-01 | 0.0596 |
| 9270 | ITGB1BP1 | LZE21T | Human | Esophagus | ESCC | 2.61e-04 | 4.43e-01 | 0.0655 |
| 9270 | ITGB1BP1 | LZE6T | Human | Esophagus | ESCC | 5.81e-10 | 6.17e-01 | 0.0845 |
| 9270 | ITGB1BP1 | P1T-E | Human | Esophagus | ESCC | 1.52e-09 | 5.19e-01 | 0.0875 |
| 9270 | ITGB1BP1 | P2T-E | Human | Esophagus | ESCC | 1.05e-32 | 7.46e-01 | 0.1177 |
| 9270 | ITGB1BP1 | P4T-E | Human | Esophagus | ESCC | 5.40e-38 | 9.82e-01 | 0.1323 |
| 9270 | ITGB1BP1 | P5T-E | Human | Esophagus | ESCC | 3.34e-48 | 9.79e-01 | 0.1327 |
| 9270 | ITGB1BP1 | P8T-E | Human | Esophagus | ESCC | 7.49e-31 | 5.27e-01 | 0.0889 |
| 9270 | ITGB1BP1 | P9T-E | Human | Esophagus | ESCC | 3.25e-28 | 6.81e-01 | 0.1131 |
| 9270 | ITGB1BP1 | P10T-E | Human | Esophagus | ESCC | 1.51e-57 | 1.10e+00 | 0.116 |
| 9270 | ITGB1BP1 | P11T-E | Human | Esophagus | ESCC | 6.14e-24 | 1.15e+00 | 0.1426 |
| 9270 | ITGB1BP1 | P12T-E | Human | Esophagus | ESCC | 4.50e-40 | 7.29e-01 | 0.1122 |
| 9270 | ITGB1BP1 | P15T-E | Human | Esophagus | ESCC | 7.10e-35 | 9.40e-01 | 0.1149 |
| 9270 | ITGB1BP1 | P16T-E | Human | Esophagus | ESCC | 9.15e-20 | 3.67e-01 | 0.1153 |
| 9270 | ITGB1BP1 | P17T-E | Human | Esophagus | ESCC | 1.15e-11 | 9.66e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001063125 | Skin | cSCC | epithelial cell migration | 115/4864 | 357/18723 | 4.64e-03 | 2.37e-02 | 115 |
| GO:004586025 | Skin | cSCC | positive regulation of protein kinase activity | 123/4864 | 386/18723 | 5.23e-03 | 2.64e-02 | 123 |
| GO:005189422 | Skin | cSCC | positive regulation of focal adhesion assembly | 14/4864 | 28/18723 | 5.47e-03 | 2.73e-02 | 14 |
| GO:000721922 | Skin | cSCC | Notch signaling pathway | 60/4864 | 172/18723 | 5.82e-03 | 2.87e-02 | 60 |
| GO:009013225 | Skin | cSCC | epithelium migration | 115/4864 | 360/18723 | 6.20e-03 | 3.04e-02 | 115 |
| GO:00513026 | Skin | cSCC | regulation of cell division | 61/4864 | 177/18723 | 7.34e-03 | 3.47e-02 | 61 |
| GO:000716224 | Skin | cSCC | negative regulation of cell adhesion | 98/4864 | 303/18723 | 7.45e-03 | 3.50e-02 | 98 |
| GO:0032231111 | Skin | cSCC | regulation of actin filament bundle assembly | 39/4864 | 105/18723 | 7.56e-03 | 3.53e-02 | 39 |
| GO:19054765 | Skin | cSCC | negative regulation of protein localization to membrane | 15/4864 | 32/18723 | 8.65e-03 | 4.00e-02 | 15 |
| GO:001081221 | Skin | cSCC | negative regulation of cell-substrate adhesion | 27/4864 | 68/18723 | 9.07e-03 | 4.16e-02 | 27 |
| GO:00019531 | Skin | cSCC | negative regulation of cell-matrix adhesion | 18/4864 | 41/18723 | 9.64e-03 | 4.31e-02 | 18 |
| GO:009013025 | Skin | cSCC | tissue migration | 115/4864 | 365/18723 | 9.81e-03 | 4.33e-02 | 115 |
| GO:000166727 | Skin | cSCC | ameboidal-type cell migration | 146/4864 | 475/18723 | 1.05e-02 | 4.58e-02 | 146 |
| GO:0032386111 | Thyroid | PTC | regulation of intracellular transport | 202/5968 | 337/18723 | 1.12e-26 | 3.93e-24 | 202 |
| GO:0033157112 | Thyroid | PTC | regulation of intracellular protein transport | 149/5968 | 229/18723 | 3.83e-25 | 1.15e-22 | 149 |
| GO:0032388112 | Thyroid | PTC | positive regulation of intracellular transport | 132/5968 | 202/18723 | 1.10e-22 | 2.57e-20 | 132 |
| GO:0090316110 | Thyroid | PTC | positive regulation of intracellular protein transport | 109/5968 | 160/18723 | 4.20e-21 | 7.79e-19 | 109 |
| GO:0006605113 | Thyroid | PTC | protein targeting | 180/5968 | 314/18723 | 6.81e-21 | 1.19e-18 | 180 |
| GO:1903829113 | Thyroid | PTC | positive regulation of cellular protein localization | 162/5968 | 276/18723 | 2.40e-20 | 3.52e-18 | 162 |
| GO:0051098113 | Thyroid | PTC | regulation of binding | 195/5968 | 363/18723 | 3.21e-18 | 3.37e-16 | 195 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ITGB1BP1 | SNV | Missense_Mutation | c.592N>A | p.Glu198Lys | p.E198K | O14713 | protein_coding | tolerated(0.25) | benign(0.185) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ITGB1BP1 | SNV | Missense_Mutation | c.83N>G | p.Ser28Cys | p.S28C | O14713 | protein_coding | tolerated(0.12) | probably_damaging(0.996) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ITGB1BP1 | SNV | Missense_Mutation | rs773209764 | c.8G>A | p.Arg3His | p.R3H | O14713 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.991) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| ITGB1BP1 | SNV | Missense_Mutation | c.83N>A | p.Ser28Tyr | p.S28Y | O14713 | protein_coding | deleterious(0.03) | probably_damaging(0.995) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ITGB1BP1 | SNV | Missense_Mutation | rs376533619 | c.317C>T | p.Pro106Leu | p.P106L | O14713 | protein_coding | tolerated(0.31) | benign(0.007) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ITGB1BP1 | SNV | Missense_Mutation | novel | c.29N>A | p.Ser10Asn | p.S10N | O14713 | protein_coding | tolerated_low_confidence(0.19) | probably_damaging(0.95) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| ITGB1BP1 | SNV | Missense_Mutation | novel | c.122G>A | p.Ser41Asn | p.S41N | O14713 | protein_coding | deleterious(0.03) | probably_damaging(0.988) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| ITGB1BP1 | SNV | Missense_Mutation | novel | c.526N>G | p.Ser176Gly | p.S176G | O14713 | protein_coding | tolerated(0.13) | possibly_damaging(0.59) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ITGB1BP1 | SNV | Missense_Mutation | novel | c.439G>A | p.Gly147Ser | p.G147S | O14713 | protein_coding | tolerated(0.27) | probably_damaging(0.999) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ITGB1BP1 | SNV | Missense_Mutation | rs771640299 | c.568N>A | p.Ala190Thr | p.A190T | O14713 | protein_coding | tolerated(0.21) | benign(0.207) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |